[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100552776":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":10,"centralContacts":18,"locations":24,"responsibleParty":41,"collaborators":10,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":10,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":51,"minAge":52,"maxAge":10,"enrollmentInfo":53,"targetDuration":10,"studyType":56,"phases":10,"briefSummary":57,"conditions":58,"keywords":10,"overallStatus":26,"whyStopped":10,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},{"fullName":5,"class":6},"Peking University First Hospital","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"different stages of individuals with Alzheimer's disease",null,[12],"Diagnostic Test: Blood biomarker",[14],{"type":15,"name":16,"description":16,"armGroupLabels":17,"otherNames":10},"DIAGNOSTIC_TEST","Blood biomarker",[9],[19],{"name":20,"role":21,"phone":22,"phoneExt":10,"email":23},"Chen Zhang","CONTACT","86+83572462","chenzizm@126.com",[25],{"facility":5,"status":26,"city":27,"state":28,"zip":29,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"RECRUITING","Beijing","Beijing Municipality","100034","China","CN",{"type":33,"coordinates":34},"Point",[35,36],116.39723,39.9075,{"lat":36,"lon":35},[39],{"name":40,"role":21,"phone":10,"phoneExt":10,"email":10},"Chen Zhang, PhD",{"type":42,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100552776","blood-biomarkers-for-screening-of-alzheimers-disease-100552776",false,"NCT06477484","Blood Biomarkers for Screening of Alzheimer's Disease","Blood-based Biomarkers for Early Alzheimer's Disease Screening","Inclusion Criteria:\n\n* Age ≥ 50 years;\n* AD (meets the 2011 NIA-AA AD diagnostic criteria), or MCI (meets the 2004 Peterson MCI diagnostic criteria), or cognitively normal subjects;\n* Signed informed consent form.\n\nExclusion Criteria:\n\n* The presence of other disorders that can cause cognitive impairment;\n* Unable to cooperate with the completion of cognitive assessment;\n* Refusal to draw blood.",true,"ALL","50 Years",{"count":54,"type":55},180,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to estimate the screen performance of blood biomarkers of interest (Aβ40 and Aβ42, P-Tau181, P-Tau217, GFAP and NfL) in patients with Alzheimer's disease (AD), mild cognitive impairment due to AD, and cognitively normal individuals. The main questions it aims to answer are:\n\n* to identify core blood biomarker suitable for early screening of AD.\n* to establish a comprehensive model for the early identification of AD.",[59,60],"Alzheimer's Disease","Blood Biomarkers","2024-06-26",{"date":63,"type":64},"2024-06-27","ACTUAL",{"date":66,"type":64},"2024-06-18",{"date":68,"type":55},"2026-03-26",{"name":5,"class":6},1]